KRYOGENE™ HAS LAUNCH THE NEW CELL FREEZING MEDIUM PRODUCT

Kryogene™ has launch the new cell freezing medium product

Kryogene™ has launch the new cell freezing medium product

Blog Article

Product Information

Kryogene™ Cell Freezing Media - CGT (FDA MasterFile) is a series of highly efficient, safe, and easy-to-use cryopreservation media optimized for the special requirements of a variety of cell and gene therapy drugs, ensuring that cells maintain optimal viability and functionality during the freezing, storage, and thawing.


Product Feature

DMSO Pre-Formulated

Serum-Free

Protein-Free

USP Components

No Ingredients

of Animal Origin

GMP-compliant Production

Sterility

Ultra low endotoxin

Cell Cryopreservation

Release Testing

Kryogene™ has launch the new cell freezing medium product(图1)

Human Immune Cell Subtype:

Cryopreserved hCD34+ Cell

Functional Tests

Kryogene™ has launch the new cell freezing medium product(图2)

Fig 1. Human Mobilized Peripheral Blood-derived hCD34+ (Donor 1) and Umbilical Cord Blood-derived hCD34+ (Donor 2, Donor 3) were isolated and cryopreserved in Kryogene™ CFM-CGT, competitor 1, respectively. After 3 months, the cells were thawed and cultured using commercial expansion kits to compare the proliferative capacity. The number of TNC (Total nucleated cell) with expansion multiplicity was calculated on day 7 and day 13, while HSPC (CD34+, High CD34+, CD34+/CD90+) expansion percentages were analyzed via flow cytometry.

Multi-Donor Cryopreserved PBMC

Functional Tests

Kryogene™ has launch the new cell freezing medium product(图3)

Fig 2. Human PBMCs derived from multiple donors were cryopreserved using Kryogene™ CFM-CGT, as well as three competitive freezing media. After thawing, cell viability and functionality were assessed. PBMCs were stimulated with PMA-Inomycin for activation, and cytokine release was measured using the CBA method. T-cell activation and phenotypes were analyzed via flow cytometry. PBMCs labeled with Celltrace were stimulated with CD3/28 beads to assess cell proliferative activity using flow cytometry.

(A) Evaluation of post-thaw cell viability

(B) Unactivated background cytokine release

(C) Detection of cytokine release following activation

(D) Analysis of cytokine release post-activation

(E) Assessment of the proportion of inactivated cell subtypes

(F) Determination of the proportion of activated cell subtypes

(G) Evalution of PBMC proliferative activity

Report this page